本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
國際腫瘤學會於新加坡亞太年度會議前夕 公開徵集引領癌症治療未來的創新研究摘要 台北2025年12月4日 /美通社/ -- 美國臨床腫瘤學會（ASCO）今日正式徵集其2026年ASCO Breakthrough 峰會學術論文摘要，邀請全球研究人員在亞洲核心地區，向具有影響力的國際腫瘤醫學專家展示並交流研究成果。 適逢ASCO首次在新加坡舉辦年度盛會，腫瘤領域專家可自即日起至2026年2月24日美國東部時間晚上11時59分（即台灣地區時間2026年2月25日下午12時59分）提交摘要。ASCO Breakthrough 將於2026年6月25日至27日舉辦，由ASCO與新加坡腫瘤學會（SSO）聯合主辦，並由亞太區多家專業學會共同協辦。 此次會議將匯聚全球腫瘤學界專家，共同探討抗癌領域的最新突破，為癌症醫護專業人士提供展示研究成果的國際平台，推動全球抗癌進程。與會者不僅能參與重要學術討論，還能從不同醫療體系和病患群體的多元視角審視自身研究成果，實現全球科研與區域實踐的深度融合。 ASCO Breakthrough 的議程策劃由來自亞太地區的知名腫瘤學權威專家共同領導，策劃團隊主席為臺北醫學大學閻雲教授。團隊成員包括ASCO前任主席、新加坡國立癌症中心Melvin Chua博士、ASCO候任主席、馬尼拉中央大學Roselle De Guzman博士、來自新加坡國立癌症中心與新加坡腫瘤學會Eileen Poon醫生，以及中山大學腫瘤防治中心兼ASCO亞太區理事會代表馬駿醫生。 2026年ASCO Breakthrough策劃委員會主席閻雲教授表示：「ASCO Breakthrough是推動科研成果轉化為實踐應用的重要平台。向峰會提交摘要，意味著站上全球舞台，不僅可以展示最新研究成果，更可推動科研發展。與會者除了可以向國際權威專家展示最新資料，同時可與他們深度交流並建立合作關係，讓具潛力的研究能從構想更快速邁向臨床應用。亞洲在推動全球腫瘤學進展方面具有獨特優勢，我們期待來自亞洲以至全球各地的優秀研究人員積極投稿，共同將卓越科研成果轉化為實際發展動力。」 ASCO現正徵集的摘要範疇涵蓋人工智慧與數位科技、乳腺癌、中樞神經系統腫瘤、發展性治療等多個領域。其他細分類別包括晚期疾病、抗體藥物偶聯物、醫療器材及發明等。 所有獲接納的摘要將以《臨床腫瘤學雜誌》（Journal of Clinical Oncology）增刊形式在網上發表。同時，峰會也接受進行中試驗（TPS）摘要提交。來自中低收入國家的研究人員可在提交摘要時申請費用減免。 回顧2024年，ASCO Breakthrough 在日本橫濱舉辦，匯聚了來自亞太地區及全球超過35個國家和地區的790位腫瘤學專家。2026年ASCO Breakthrough預計將於2025年12月開放報名。 如欲提交摘要及瀏覽報名詳情，請到訪breakthrough.asco.org。 如欲提交摘要，請按此處。 關於美國臨床腫瘤學會 美國臨床腫瘤學會（ASCOR）成立於1964年，始終堅信知識能戰勝癌症。ASCO與臨床腫瘤協會合共代表逾五萬名服務癌症病人的腫瘤科醫護人員。ASCO透過推動研究、教育及優質醫療服務，致力對抗癌症，以實現預防與治癒癌症的願景，冀讓每位倖存者重獲健康。ASCO旗下基金會Conquer CancerR通過資助腫瘤學全週期的開創性研究和教育，為學會提供重要支持。如欲瞭解更多詳情，請瀏覽官方網頁 www.ASCO.org，並關注我們的官方Facebook、X、LinkedIn、Instagram、Bluesky及YouTube平台。 關於ASCO Breakthrough ASCO Breakthrough是一年一度的亞太腫瘤學盛會，聚焦革新研究與跨學科專家觀點，探討正迅速改變癌症治療格局的最新科研成果、臨床技術進展及治療方案。峰會透過專題討論、病例研討及摘要報告等形式，匯聚志同道合的專業人士，促進全球癌症治療發展，遘向戰勝癌症的目標。
誠邀全球學者提交腫瘤學研究摘要 國際腫瘤學會於新加坡亞太年度會議前夕 公開徵集引領癌症治療未來的創新研究摘要 香港2025年12月4日 /美通社/ -- 美國臨床腫瘤學會（ASCO）今日正式徵集其2026年ASCO Breakthrough 峰會學術論文摘要，邀請全球研究人員在亞洲核心地區，向具有影響力的國際腫瘤醫學專家展示並交流研究成果。 適逢ASCO首次在新加坡舉辦年度盛會，腫瘤領域專業人士可自即日起至2026年2月24日美國東部時間晚上11時59分（即香港時間2026年2月25日下午12時59分）提交摘要。ASCO Breakthrough 將於2026年6月25日至27日舉辦，由ASCO與新加坡腫瘤學會（SSO）聯合主辦，並由亞太區多家專業學會共同協辦。 此次會議將匯聚全球腫瘤學界專家，共同探討抗癌領域的最新突破，為癌症醫護專業人士提供展示研究成果的國際平台，推動全球抗癌進程。與會者不僅能參與重要學術討論，還能從不同醫療體系和病患群體的多元視角審視自身研究成果，實現全球科研與區域實踐的深度融合。 ASCO Breakthrough 的議程策劃由來自亞太地區的知名腫瘤學權威專家共同領導，策劃團隊主席為臺北醫學大學閻雲教授。團隊成員包括ASCO前任主席、新加坡國立癌症中心Melvin Chua博士、ASCO候任主席、馬尼拉中央大學Roselle De Guzman博士、來自新加坡國立癌症中心與新加坡腫瘤學會Eileen Poon醫生，以及中山大學腫瘤防治中心兼ASCO亞太區理事會代表馬駿醫生。 2026年ASCO Breakthrough 策劃委員會主席閻雲教授表示：「ASCO Breakthrough是推動科研成果轉化為實踐應用的重要平台。向峰會提交摘要，意味着站上全球舞台，不僅可以展示最新研究成果，更可推動科研發展。與會者除了可以向國際權威專家展示最新數據，亦可與他們深度交流並建立合作關係，將具潛力的研究概念加快推進至臨床應用。亞洲在推動全球腫瘤學進展方面具有獨特優勢，我們期待來自亞洲以至全球各地的優秀研究人員積極投稿，共同將卓越科研成果轉化為實際發展動力。」 ASCO現正徵集的摘要範疇涵蓋人工智能與數碼科技、乳腺癌、中樞神經系統腫瘤、發展性治療等多個領域。其他細分類別包括晚期疾病、抗體藥物偶聯物、醫療器械及發明等。 所有獲接納的摘要將以《臨床腫瘤學雜誌》（Journal of Clinical Oncology）增刊形式在網上發表。同時，峰會也接受進行中試驗（TPS）摘要提交。來自中低收入國家的研究人員可在提交摘要時申請費用減免。 回顧2024年，ASCO Breakthrough在日本橫濱舉辦，匯聚了來自亞太地區及全球超過35個國家和地區的790位腫瘤學專家。2026年ASCO Breakthrough預計將於2025年12月開放報名。 如欲提交摘要及瀏覽報名詳情，請到訪breakthrough.asco.org。 如欲提交摘要，請按此處。 關於美國臨床腫瘤學會 美國臨床腫瘤學會（ASCO®）成立於1964年，始終堅信知識能戰勝癌症。ASCO與臨床腫瘤協會合共代表逾五萬名服務癌症病人的腫瘤科醫護人員。ASCO透過推動研究、教育及優質醫療服務，致力對抗癌症，以實現預防與治癒癌症的願景，冀讓每位倖存者重獲健康。ASCO旗下基金會Conquer Cancer®通過資助腫瘤學全週期的開創性研究和教育，為學會提供重要支持。如欲了解更多詳情，請瀏覽官方網頁 www.ASCO.org，並關注我們的官方Facebook、X、LinkedIn、Instagram、Bluesky及YouTube平台。 關於ASCO Breakthrough ASCO Breakthrough是一年一度的亞太腫瘤學盛會，聚焦革新研究與跨學科專家觀點，探討正迅速改變癌症治療格局的最新科研成果、臨床技術進展及治療方案。峰會透過專題討論、病例研討及摘要報告等形式，匯聚志同道合的專業人士，促進全球癌症治療發展，遘向戰勝癌症的目標。
Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of annual Asia-Pacific meeting in Singapore SINGAPORE, Dec. 4, 2025 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) today launched its call for abstracts for its 2026 Breakthrough meeting, offering researchers globally the opportunity to present and discuss findings with an influential, international audience of cancer care professionals in the heart of Asia. In advance of the annual conference, held for the first-time in Singapore, oncology professionals can submit abstracts to ASCO Breakthrough from today until 11:59 PM on 24 February 2026, Eastern Time (12:59 PM, Singapore Standard Time, 25 February 2026). ASCO Breakthrough takes place from 25-27 June 2026, co-hosted by ASCO and the Singapore Society of Oncology, along with other collaborating societies in the Asia Pacific region. The meeting provides cancer care professionals the opportunity to have their research featured when the global oncology community comes together to explore the latest advances and accelerate progress towards conquering cancer worldwide. Alongside critical dialogues, cancer care professionals will also be able to see their work through the lens of different healthcare systems and patient populations, bridging global science and regional expertise. ASCO Breakthrough's program leadership comprises esteemed cancer care professionals from the region, chaired by Dr. Yun Yen, Taipei Medical University, alongside Past Chair Dr. Melvin Chua, National Cancer Centre Singapore; Chair-Elect Dr. Roselle De Guzman, Manila Central University; Dr. Eileen Poon, National Cancer Centre Singapore and the Singapore Society of Oncology, as well as Dr. Jun Ma, Sun Yat-sen University Cancer Centre and ASCO Asia Pacific Regional Council Representative. "ASCO Breakthrough is a powerful catalyst where science meets real-world impact. Submitting an abstract to the meeting means joining a global stage where new science is not just presented, but advanced. It's an opportunity to showcase novel data, engage with international experts, and build collaborations that can fast-track promising research from concept to clinic. Asia has a unique opportunity to drive global oncology forward, and I hope to see researchers from the region and beyond contribute their science to the meeting and together, amplify good science into real momentum," said Dr. Yun Yen, Program Committee Chair, 2026 ASCO Breakthrough. ASCO is accepting abstracts across tracks ranging from artificial intelligence and digital technology to breast cancer, central nervous system tumors, developmental therapeutics and more. Additional subcategories include advanced disease, antibody drug conjugates and devices, and inventions. All accepted abstracts will be published online as part of the Journal of Clinical Oncology supplement. Trials in Progress (TPS) abstracts will also be accepted. Professionals in Low-and-Middle-Income Countries (LMICs) can apply for fee waivers at the time of submission. In 2024, the Breakthrough meeting welcomed 790 experts from more than 35 countries in the Asia-Pacific region and around the world in Yokohama. Registrations for the 2026 ASCO Breakthrough will open in December 2025. To submit abstracts and view more details about registration, visit: breakthrough.asco.org About the American Society of Clinical Oncology Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer®, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer's full continuum. Learn more at www.ASCO.org, and follow us on Facebook, X, LinkedIn, Instagram, Bluesky, and YouTube. About ASCO Breakthrough ASCO Breakthrough is an annual Asia-Pacific oncology meeting offering novel research and expert, multidisciplinary perspectives on the newest scientific findings, clinical and technology advances, and treatment approaches that are rapidly changing cancer care. Take part in insightful sessions, case discussions, and abstract presentations, and join a community of like-minded professionals to contribute, together, toward conquering cancer.
CHICAGO, Dec. 4, 2025 /PRNewswire/ -- AlphaBitCore today announced the launch of its Model Context Protocol (MCP) Federated Access Platform, a unified control layer that lets enterprises connect AI to real work across their business, using the systems they already have. Instead of adding yet another agent, workflow tool, or RPA product, AlphaBitCore gives companies one place to plug in models, agents, tools, and data, then decide what AI is allowed to do and where. The result is simple to understand - AI that can actually move tickets, update records, kick off approvals, and close loops in production, while the enterprise keeps a single, clear view of how it all runs. "Most enterprises do not have an AI problem. They have an AI sprawl problem," said James Rhodes, Co-Founder and CEO of AlphaBitCore. "We built AlphaBitCore so you can manage your entire AI stack in one place and finally let AI do real work inside your business, not just sit in a chatbot." Banks can use AlphaBitCore to let AI prepare credit memos, gather documents, run risk checks, and send files for approval, all inside existing banking, risk, and compliance systems. Product and engineering teams can ask AI to draft PRDs, open tickets, assign work, and keep documentation in sync, using the same Jira, code, and knowledge tools they already rely on. In each case, AI is no longer a separate assistant on the side. It works inside the normal tools and workflows; under rules the company sets once and reuses everywhere. This is where AlphaBitCore differentiates itself from traditional agents, workflow tools, and RPA. Those products focus on single processes, single teams, or single vendors. AlphaBitCore is designed to sit above them as the platform where enterprises manage the whole AI estate. It connects out to MCP servers, gateways, and APIs, then pulls them into one governed environment so leaders can see what AI is doing, where it is connected, and what value it is creating. Safety and security are built into this platform, but not as a brake. By centralizing identity, access, and auditing, AlphaBitCore lets risk and compliance teams set policy once so that product, operations, and engineering teams can move faster without renegotiating every new use case. The promise is straightforward: one place to control your AI stack, so you can scale AI across the business with confidence. To support early adopters, AlphaBitCore is opening a limited Early Access Program for selected global institutions. Participants will receive sandbox environments, starter toolkits for banking and developer workflows, and direct collaboration with the AlphaBitCore team to identify and launch their first high value AI powered processes. "Enterprises are tired of impressive demos that never reach production," said GK, Co-Founder of AlphaBitCore. "Early Access is about getting a few critical workflows live, proving value quickly, and giving teams a single platform they can grow with." About AlphaBitCore AlphaBitCore is a next generation AI infrastructure company focused on helping enterprises manage and scale their AI stack. Its MCP Federated Access Platform provides a unified control layer that lets AI agents and humans operate across enterprise systems with full compliance, observability, and traceability. The company serves financial institutions, wealth managers, digital banks, insurers, and global enterprises that want to move from AI experiments to a single, governed platform for AI in production. Website: https://www.alphabitcore.com
SYDNEY, Dec. 4, 2025 /PRNewswire/ -- X-Design, the AI branding platform built specifically for the brick-and-mortar economy, today announced it has achieved the #1 Product of the Day on Product Hunt. This milestone marks the launch of its new AI Agent, an autonomous design partner that enables cafés, fitness studios, and service providers to build and maintain a consistent, professional brand identity in minutes. While many AI tools focus on isolated tasks, X-Design's AI Agent creates a unified workflow powered by long-term contextual memory. It serves as an always-on brand manager, ensuring that everything from a shop's logo to its Instagram posts retains the brand's unique "Visual DNA" without requiring users to repeat themselves. Solving the "Visual Consistency" Struggle for SMBsBuilt on insights from over 500 beta users in retail, F&B, and wellness sectors, the Agent addresses the biggest challenge for small businesses: fragmentation. "Small business owners wear every hat, but 'Chief Design Officer' shouldn't have to be one of them," said Elvis, Founder of X-Design. "Reaching No. 1 on Product Hunt validates our belief that branding should be accessible to everyone. We aren't just generating logos; we are giving local shops a partner that remembers their specific style, tone, and preferences, effectively eliminating the need to 'brief' the designer every time they need a new asset." Key Capabilities Powering the Win1. A Full Brand System in Under 10 MinutesInstead of piecing together designs from different tools, users can chat with the AI Agent to generate a complete identity system, including unique logos, color palettes, and typography, in a single conversation. The AI instantly visualizes these elements on real-world mockups like storefront signage and packaging. In beta testing, this streamlined workflow allowed 92% of users to finalize a production-ready brand identity within just 10 minutes.2. The "Always-On" Brand ManagerOnce a brand is established, the Agent automatically saves all assets into a dynamic Brand Kit. This ensures that when a user requests a new asset, such as a holiday promo poster or a menu update, the system generates designs that strictly follow the stored brand guidelines without needing fresh instructions. This automated consistency helped beta users achieve 35% higher visual coherence across their marketing materials.3. Real-World Ready OutputAddressing the specific needs of physical businesses, the Agent produces files formatted for both digital screens and physical print. Whether users need menus, flyers, event signage, or promo cards, the output supports high-resolution formats (including SVG) ready for local print shops, eliminating the need for format conversion.4. AI Photography That Elevates SalesThe platform transforms everyday snapshots into professional marketing assets. With a simple command like "turn this into a studio-quality product photo," the AI enhances lighting, composition, and places products in realistic, on-brand environments. These high-quality visuals are optimized for Instagram, Google Maps, and digital displays, driving up to 41% higher engagement on product posts during early access. Pricing and AvailabilityX-Design is available worldwide at https://www.x-design.com/. The platform offers:1) Free Plan: Essential features for new businesses.2) Pro Plan:Full AI access, unlimited brand assets, and high-res downloads.3) Enterprise Plan: Custom solutions for larger teams. About X-DesignX-Design empowers the heart of the local economy—small businesses—to compete visually with major chains. By combining generative AI with professional design principles, X-Design helps independent sellers create and apply cohesive visual identities across all touchpoints without the complexity or cost of traditional agencies. Press & Partnership ContactEmail: info@x-design.com Website: https://www.x-design.com
NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Administration ("NMPA") of the PRC, with the proposed indication for the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma (CCA) who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, Tinengotinib has been granted Breakthrough Therapy Designation by the NMPA for the treatment of CCA. Disclaimer: This article serves as a press release by TransThera to disclose the company's latest developments. It is not intended as a product promotion advertisement and does not constitute the company's investment advice. About Tinengotinib Tinengotinib is an internally discovered, registrational clinical stage, multi-kinase inhibitor that exerts antitumor effects by targeting FGFRs/VEGFRs, Aurora kinases and Janus kinases (JAK). Ongoing clinical trials in the US and China have revealed the potential of Tinengotinib to be efficacious in various solid tumors. It was granted the Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the FDA for the treatment of CCA, the Breakthrough Therapy Designation (BTD) by the NMPA in China, the Orphan Drug Designation (ODD) for the treatment of biliary tract cancer by the EMA. About TransThera TransThera is a clinical demand-oriented, registrational clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. Further aided by in-depth study of translational medicine and drug design, TransThera aims to develop first-in-class or best-in-class drug candidates strategically positioned to meet urgent clinical needs on a global scale. For more information, please visit www.transthera.com
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
